🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. LMT (atorvastatin, simvastatin, or rosuvastatin)

    Regeneron UK Limited

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  2. LOPERAMIDE , Ultra-Levura 250 mg cápsulas duras, Placebo to Saccharomyces boulardii

    Biocodex

    Non-constipated Irritable Bowel Syndrome (IBS)

    phase 3 small molecule active

    1 trial

  3. LOU064, CLINDAMYCIN , Placebo to remibrutinib (lou064) 0 mg matching 00 mg film-coated tablet, LOU064, Placebo to remibrutinib (lou064) 0 mg matching 00 mg film-coated tablet, TRIAMCINOLONE , -

    Novartis Pharmaceuticals

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  4. LOU064, COLESTYRAMINE , TERIFLUNOMIDE, Placebo to teriflunomide 14 mg capsule, hard, Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, MEDICINAL CHARCOAL

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  5. LOU064, Placebo to Remibrutinib (LOU064) XX mg film-coated tablet, -, -

    Novartis Pharmaceuticals

    Chronic Inducible Urticaria (CINDU)

    phase 3 small molecule active

    1 trial

  6. LOU064, Placebo to teriflunomide 14 mg capsule, hard, COLESTYRAMINE , Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, TERIFLUNOMIDE, MEDICINAL CHARCOAL

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  7. LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin

    Lacuna Pharma Pty Ltd

    Developmental and Epileptic Encephalopathies (DEEs)

    phase 3 small molecule active

    1 trial

  8. LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin

    Lacuna Pharma Pty Ltd

    Developmental and Epileptic Encephalopathies (DEE)

    phase 3 small molecule active

    1 trial

  9. Lactose monohydrate, Melatonine Tiofarma 5 mg tabletten

    Disc Medicine

    Chronic low back pain

    phase 3 small molecule active

    1 trial

  10. Lansoprazole

    Takeda

    Stomach Ulcer

    phase 3 small molecule completed

    2 trials

  11. Lansoprazole and naproxen and aspirin

    Takeda

    Osteoarthritis

    phase 3 small molecule completed

    1 trial

  12. Lansoprazole microgranules suspension

    Takeda

    Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    1 trial

  13. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen

    NovoThirteen

    Type 1 Diabetes

    phase 3 small molecule active

    1 trial

  14. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, Ozempic 2 mg solution for injection in pre-filled pen, Ozempic 1 mg solution for injection in pre-filled pen

    NovoThirteen

    Participants with T2D and overweight

    phase 3 small molecule active

    1 trial

  15. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, insulin icodec 700 U/mL PDS290

    NovoThirteen

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  16. Lapaquistat acetate

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    4 trials

  17. Lapaquistat acetate and atorvastatin

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    2 trials

  18. Lapaquistat acetate and current lipid-lowering treatment

    Takeda

    Hypercholesterolemia

    phase 3 small molecule terminated

    1 trial

  19. Lapaquistat acetate and rosuvastatin

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  20. Lapaquistat acetate and simvastatin

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    2 trials

  21. Lapaquistat acetate and stable statin therapy

    Takeda

    Hypercholesterolemia

    phase 3 small molecule terminated

    2 trials

  22. Laquinimod

    Teva Pharma GmbH

    Relapsing Multiple Sclerosis

    phase 3 small molecule terminated

    2 trials

  23. Laquinimod

    Teva Pharma GmbH

    Multiple Sclerosis

    phase 3 small molecule completed

    3 trials

  24. Laquinimod

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule terminated

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources